文献速递心律失常

非维生素K拮抗剂口服抗凝药在合并非瓣膜性房颤与阿司匹林治疗患者中的疗效与安全性:随机试验荟萃分析

Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
PubMed 文献 · Circulation · 2017-11-03

该研究基于4项随机对照试验中接受阿司匹林治疗的非瓣膜性房颤患者亚组(n=21 722),比较NOACs与VKAs的疗效与安全性。结果显示NOACs在降低卒中或系统性栓塞、血管性死亡及颅内出血方面优于VKAs,大出血风险与VKAs相当。

要点

  • 在主要使用低剂量阿司匹林的非瓣膜性房颤患者中,NOACs较VKAs更有效降低卒中或系统性栓塞(HR 0.78)。
  • NOACs较VKAs显著降低颅内出血风险(HR 0.38),大出血风险相当(HR 0.83)。
  • 对于需合并阿司匹林治疗的非瓣膜性房颤患者,NOACs可能较VKAs更安全有效。

核心结论

  • 在合并非瓣膜性房颤与阿司匹林治疗的患者中,NOACs较VKAs可能更安全且更有效。

研究设计与样本

  • 系统综述与基于研究的荟萃分析,纳入4项比较VKAs与NOACs的随机对照试验中接受阿司匹林治疗的非瓣膜性房颤患者亚组(n=21 722)。

主要发现

  • NOACs较VKAs降低卒中或系统性栓塞风险(HR 0.78;95%CI 0.67-0.91)。
  • NOACs较VKAs降低血管性死亡风险(HR 0.85;95%CI 0.76-0.93)。
  • NOACs与大出血风险相当(HR 0.83;95%CI 0.69-1.01)。
  • NOACs较VKAs显著降低颅内出血风险(HR 0.38;95%CI 0.26-0.56)。

临床怎么用

  • 对于非瓣膜性房颤需合并阿司匹林治疗的患者,可优先考虑NOACs而非VKAs。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current guidelines recommend non-vitamin K antagonist oral anticoagulants (NOACs) as the first-choice therapy in patients with nonvalvular atrial fibrillation because these drugs have several benefits over the vitamin K antagonists (VKAs). It is unknown whether these benefits remain when NOACs have to be combined with aspirin therapy. To assess the efficacy and safety of NOACs compared with VKAs in patients with atrial fibrillation and concomitant aspirin therapy, we conducted a systematic review and study-based meta-analysis of published randomized controlled trials. METHODS: A systematic electronic literature search was done in MEDLINE, EMBASE, and Cochrane CENTRAL Register of Controlled Trials for studies including published data of patients ≥18 years of age with nonvalvular atrial fibrillation, randomized to either VKAs or NOACs, or receiving aspirin therapy at any time during the study that report all-cause stroke or systemic embolism, vascular death, myocardial infarction, major bleeding, or intracranial hemorrhage as an outcome. Hazard ratios (HRs) with 95% confidence intervals (CIs) for each outcome were extracted from the individual studies and pooled with random-effects meta-analysis. RESULTS: This study-based meta-analysis was restricted to the subgroups of patients on aspirin therapy (n=21 722) from 4 randomized controlled trials comparing VKAs and NOACs (n=71 681) in nonvalvular atrial fibrillation. In this meta-analysis including patients on mainly low-dose aspirin, NOACs were found to be more effective (outcome of stroke or systemic embolism: HR, 0.78; 95% CI, 0.67-0.91; vascular death: HR, 0.85; 95% CI, 0.76-0.93) and as safe as VKAs with respect to major bleeding (HR, 0.83; 95% CI, 0.69-1.01). NOACs were safer with respect to the reduction of intracranial hemorrhage (HR, 0.38; 95% CI, 0.26-0.56). CONCLUSIONS: This study-based meta-analysis shows that it may be both safer and more effective to use NOACs compared with VKAs to treat patients with nonvalvular atrial fibrillation and concomitant aspirin therapy.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Bennaghmouch N, de Veer AJWM, Bode K, et al. Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials. Circulation. 2017. PMID: 29101289. doi:10.1161/CIRCULATIONAHA.117.028513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。